Spectral AI (MDAI) Earnings Date & Reports

Key Takeaways

• Spectral AI (MDAI) is scheduled to report third quarter 2026 results on Tuesday, November 10, 2026, after the Nasdaq market closes, followed by a conference call at 5:00 p.m. Eastern Time.
• Wall Street consensus calls for earnings per share (EPS) of approximately -$0.14 and revenue of roughly $5.33 million, implying year-over-year revenue growth of about 40%.
• The report arrives shortly after the company received U.S. Food and Drug Administration (FDA) De Novo clearance for its DeepView AI System for the burn indication, a milestone that shifts the focus toward commercialization.
• Management has reaffirmed 2026 research and development (R&D) revenue guidance of approximately $18.5 million, which does not include meaningful contributions from DeepView system sales.
• In the same period a year earlier, Spectral AI posted revenue of $3.79 million and an EPS of -$0.13, providing a low base for the expected top-line comparison.
• Explore more about the ticker's Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
• Discover automated market insights by exploring Trending AI Robots.

Earnings Context and Why It Matters

Spectral AI's third quarter 2026 update carries outsized weight because the company is transitioning from a research-stage developer into a commercial medical-device business. The quarter was the first full reporting period following the FDA's De Novo clearance of its DeepView AI System for burn care, a regulatory approval that opened the door to initial U.S. sales. Investors will therefore look beyond the headline numbers and toward signals about commercial launch timing, funding from the Biomedical Advanced Research and Development Authority (BARDA), and expense discipline. With revenue still driven almost entirely by government contracts and no product sales yet recorded, the report offers a key checkpoint on whether the company can sustain its narrowed losses while positioning for its first commercial placements expected later in the year.

Earnings Expectations

Analysts expect Spectral AI to report an EPS of about -$0.14 on revenue near $5.33 million for the third quarter of 2026, according to consensus estimates. That revenue figure would represent growth of roughly 40% from the $3.79 million recorded in the third quarter of 2025, when the company posted a net loss of $3.6 million, or -$0.13 per share. The anticipated increase reflects a partial recovery in BARDA contract activity after prior-year revenue was depressed by the completion of the base phase of the BARDA Project BioShield contract.

On the guidance front, management has reaffirmed full-year 2026 R&D revenue of approximately $18.5 million, excluding any significant contribution from DeepView system sales. Key metrics investors will monitor include gross margin, which dipped to 31.6% in the second quarter as the company entered a cost-sharing phase with BARDA, as well as cash levels, operating expenses, and any updated commentary on the pace of initial U.S. and U.K. commercial placements.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. The platform allows users to scan thousands of stocks and ETFs with customizable filters, including industry, market capitalization, technical indicators, price patterns, and performance metrics. By surfacing trade ideas, trending stocks, and breakout candidates, the screener can help identify market opportunities more efficiently than manual screening. For investors tracking names such as Spectral AI, the AI Screener offers a practical way to stay ahead of shifting market conditions.

Market Reaction and Investor Sentiment

Sentiment heading into the third quarter report centers on the company's recent regulatory breakthrough rather than its near-term profitability. Following the FDA De Novo clearance of the DeepView AI System, attention has shifted to execution—specifically, how quickly Spectral AI can convert its BARDA-supported installations into recurring revenue and expand internationally. The stock remains speculative and thinly capitalized, which can amplify volatility around earnings announcements. Risks heading into the print include the pace of commercial rollouts, margin pressure tied to the BARDA cost-sharing arrangement, and any updates on cash runway. Because the company has beaten consensus EPS estimates in only three of its last seven quarters, investors may react more to forward guidance and commercialization commentary than to the headline figures themselves.

Forward Outlook and Key Factors to Monitor

Looking ahead, the most important item to watch is the timeline for the first commercial sales of the DeepView AI System. Management has indicated that initial placements in the U.S. and U.K. could occur before the end of 2026, with a more material revenue ramp expected in 2027 and 2028. Progress on BARDA-funded installations—potentially supporting up to 30 initial systems and additional units over time—will be a direct signal of near-term traction.

Investors should also monitor gross margin trends as the company operates under its BARDA cost-sharing structure. The second quarter's 31.6% gross margin, down from 45.2% a year earlier, reflects this transition and could remain pressured until higher-margin recurring software and service revenue scales up.

Additional catalysts include expanded UKCA clearance, which the company anticipates in the fourth quarter of 2026, and the planned initiation of a Triage and Treatment Outcome Study designed to demonstrate the clinical benefits of the DeepView system. Finally, balance-sheet strength remains in focus, with roughly $14 million in cash at the end of the second quarter and management indicating it has sufficient working capital for at least a year, though future capital needs could shift if circumstances change.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations